Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Coherus Oncology's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHRS vs NAUT, AVXL, SLNCF: FCF Margin % Comparison
For the Biotechnology subindustry, Coherus Oncology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus Oncology (CHRS) has a FCF Margin % of -433.98% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Coherus Oncology and its competitors. According to the industry distribution chart, Coherus Oncology ranks #652 out of 953 companies in the Biotechnology industry, placing it in the top 68.4%.
Is Coherus Oncology's FCF Margin % too high?
Coherus Oncology's current FCF Margin % is -433.98%. Based on the distribution chart, Coherus Oncology ranks #652 out of 953 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Coherus Oncology has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's FCF Margin % compare to NAUT and AVXL?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #652 out of 953 companies for FCF Margin %. This places Coherus Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Coherus Oncology and its competitors. Coherus Oncology's current FCF Margin % is -433.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (CHRS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.94, compared to a current price of $1.27 — trading 35.1% above its estimated fair value. The current FCF Margin % is -433.98%. Coherus Oncology's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Coherus Oncology (CHRS), the current FCF Margin % is -433.98% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (CHRS) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of $1.27 is trading 35.1% above its estimated GF Value™ of $0.94.
GuruFocus considers Coherus Oncology to be Significantly Overvalued.
Key valuation signals for CHRS:
FCF Margin %: -433.98%
GF Value™: $0.94 vs. price of $1.27 (35.1% above fair value)
No single metric tells the full story. See the CHRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
42GF Score
Get the complete analysis for CHRS
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHRS has been successfully added to your 
